亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma

阿帕蒂尼 医学 肝细胞癌 肿瘤科 内科学 总体生存率 存活率 完全响应 癌 化疗 梅德林 无进展生存期 离格
作者
Rong Ding,Jin‐Feng Bai,Zhi‐Cheng Jin,Yu‐Dong Xiao,Jian‐Jian Chen,Xiao-Li Zhu,Yujing Xin,Jin‐Zhang Chen,Jun Tie,Kang-Shun Zhu,Lan Zhang,Hai-Bin Shi,Rui-Bao Liu,Aibing Xu,Fanpu Ji,Ming‐Sheng Huang,Jian‐Song Ji,Chun‐Wang Yuan,W. B. Yang,Guo‐Hui Xu
出处
期刊:Alimentary Pharmacology & Therapeutics [Wiley]
卷期号:63 (12): 1617-1625 被引量:3
标识
DOI:10.1111/apt.70612
摘要

BACKGROUND: This real-world study aimed to evaluate and compare the efficacy and safety of two treatment strategies for advanced hepatocellular carcinoma (HCC): transarterial chemoembolisation (TACE) combined with camrelizumab and apatinib versus camrelizumab and apatinib alone. METHODS: In this nationwide, multi-centre retrospective cohort study, data were collected on patients with advanced HCC who received either TACE combined with camrelizumab and apatinib (T-C-A) or camrelizumab and apatinib alone (C-A) between January 2018 and December 2022. To reduce potential bias, stabilised inverse probability of treatment weighting (sIPTW) was applied. The primary outcome was overall survival (OS), while secondary outcomes included progression-free survival (PFS), objective response rate (ORR) based on RECIST v1.1 criteria, and safety. RESULTS: A total of 252 HCC patients were included (T-C-A group, n = 183; C-A group, n = 69). Among them, 210 were males and 42 were females, with a median age of 54 years. After sIPTW, the median OS was significantly longer in the T-C-A group compared to the C-A group (24.2 months [95% CI: 21.4-33.4] vs. 15.2 months [95% CI: 9.8-21.0]; p < 0.001). The T-C-A group also demonstrated a significantly improved median PFS of 10.1 months [95% CI: 8.8-12.2], compared to 4.9 months [95% CI: 4.0-12.5] in the C-A group (p < 0.001). Further, the ORR was higher in the T-C-A group. Grade 3/4 adverse events were reported in 12.0% of patients in the T-C-A group and 14.5% in the C-A group. CONCLUSION: The combination of TACE with camrelizumab and apatinib suggests potential survival advantages for patients with advanced HCC while maintaining an acceptable safety profile.(Study series number CHANCE 2311).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CHENG发布了新的文献求助10
刚刚
CAOHOU的应助被sjyu1985采纳,获得10
2秒前
2秒前
舒适的严青完成签到,获得积分10
5秒前
yizhiyang发布了新的文献求助10
7秒前
lyp完成签到 ,获得积分10
11秒前
11秒前
yyf完成签到 ,获得积分10
11秒前
CHENG完成签到,获得积分10
14秒前
16秒前
wxsaty完成签到 ,获得积分10
17秒前
春风暮雪发布了新的文献求助10
19秒前
25秒前
27秒前
平常心完成签到,获得积分10
34秒前
35秒前
英俊的铭的应助被科研通管家采纳,获得30
35秒前
36秒前
37秒前
39秒前
40秒前
冰凌发布了新的文献求助10
43秒前
冰凌发布了新的文献求助10
43秒前
冰凌发布了新的文献求助10
43秒前
冰凌发布了新的文献求助10
44秒前
感动的怀寒完成签到 ,获得积分10
44秒前
追寻从寒发布了新的文献求助10
45秒前
背后冬萱完成签到,获得积分10
46秒前
冰凌发布了新的文献求助10
47秒前
酷酷云朵完成签到,获得积分10
48秒前
朴实的绮兰完成签到 ,获得积分10
49秒前
ll完成签到 ,获得积分10
50秒前
sjyu1985完成签到,获得积分10
54秒前
执着访云完成签到,获得积分10
57秒前
SciGPT的应助被追寻从寒采纳,获得10
1分钟前
1分钟前
1分钟前
zhy关闭了zhy的文献求助
1分钟前
1分钟前
Ava的应助被花痴的文涛采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195028
求助须知:如何正确求助?哪些是违规求助? 9580753
关于积分的说明 21872602
捐赠科研通 7794788
什么是DOI,文献DOI怎么找? 3437855
关于科研通互助平台的介绍 2561176
邀请新用户注册赠送积分活动 2484562